Impact Factor 4.137 | CiteScore 4.28
More on impact ›

Mini Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Oncol. | doi: 10.3389/fonc.2019.01287

Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications

  • 1University of California, San Francisco, United States

The increasing number of patients with sequenced prostate cancer genomes enables us to study not only individual oncogenic mutations, but also capture the global burden of genomic alterations. Here we review the extent of tumor genome mutations and chromosomal structural variants in various clinical states of prostate cancer, and the related prognostic information. Next, we discuss the underlying mutational processes that give rise to these various alterations, and their relationship to the various molecular subtypes of prostate cancer. Finally, we examine the relationships between the tumor mutation burden of castration-resistant prostate cancer, DNA repair defects, and response to immune checkpoint inhibitor therapy.

Keywords: prostate cancer, Tumor mutation burden (TMB), copy number alteration burden, Structural variant (SV), aneuploidy and polyploidy, mismatch repair (MMR) deficiency, Immune checkpoint inhibitor (ICI)

Received: 05 Sep 2019; Accepted: 06 Nov 2019.

Copyright: © 2019 Ryan and Bose. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Rohit Bose, University of California, San Francisco, San Francisco, 94143, California, United States,